Back

Flecainide in the treatment of high premature ventricular contractions burden: preliminary results from the UNIFLECA study

13 April 2026 (08:30 - 09:15)
Organised by: Logo
Congress Presentation Part of: Antiarrhythmic drugs Antiarrhythmic Drug Treatment EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Sotirios Kotoulas

Asklepieion Voulas General Hospital, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
Results of a national survey on ethacizine for atrial fibrillation treatment in real practice as a part of a patient oriented approach
Professor N. Sydorova (Kiev, UA)
Abstract Slides Video
Presentation thumbnail
Effect of sodium-glucose cotransporter 2 inhibitors (SGLT2) on the occurrence of tachyarrhythmias in patients with heart failure with reduced ejection fraction
Doctor J. Serrano Silva (Jerez de la Frontera, ES)
Abstract Slides Video
Presentation thumbnail
The influence of digoxin on outcomes in remotely monitored patients with implantable cardioverter-defibrillators
Doctor M. Dyrbus (Zabrze, PL)
Abstract Slides Video
Presentation thumbnail
Can colchicine tame atrial fibrillation? A scoping review
Miss S. Hasan (Coventry, GB)
Abstract Slides Video
Presentation thumbnail
Comparative outcomes of amiodarone and dronedarone in atrial fibrillation: a real-world retrospective cohort study
Doctor A. Akuka (Holon, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Antiarrhythmic drugs

The Event

Event poster

EHRA 2026

13 April 2026 08:30 CET
You may be interested in
thumbnail
Congress Presentation
The UNIFLECA study. prospective cohort study on flecainide impact on persistent high premature ventricular contraction burden and induced cardiomyopathy
thumbnail
Congress Presentation
Efficacy of flecainide in patients with premature ventricular contractions-induced cardiomyopathy: Subanalysis of the UNIFLECA study
thumbnail
Congress Presentation
Effect of flecainide on complex ventricular arrhythmogenesis: insights from the prospective UNIFLECA study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources